

# Unveiling the Complexity of PCOD: Exploring Contemporary Research and Scientific Breakthroughs Review

N. Udaya Kumar<sup>1</sup>, B. P. Mallikarjuna<sup>2</sup>, K. Reefa Fathima<sup>3</sup>, P. S. Umme Hani<sup>3</sup>, S. Abul Hasan<sup>3</sup>, N. Mounika<sup>3</sup>, K. Ashok Kumar<sup>3</sup>, C. L. Sunil<sup>3</sup>

<sup>1</sup>Department of Pharmaceutical Chemistry, MB School of Pharmaceutical Sciences, Mohan Babu University, Tirupati, Andhra Pradesh, India, <sup>2</sup>Department of Pharmaceutical Chemistry, MB School of Pharmaceutical Sciences, Mohan Babu University, Tirupati, Andhra Pradesh, India, <sup>3</sup>Department of Pharmacy, Practice School, MB School of Pharmaceutical Sciences, Mohan Babu University, Tirupati, Andhra Pradesh, India

## Abstract

Polycystic ovary syndrome (PCOS) is a complex endocrine disorder that significantly impacts reproductive-aged individuals globally. This paper explores recent breakthroughs in PCOS research that have revolutionized our understanding of its multifaceted nature. It delves into advancements in the understanding of etiology and pathophysiology through genetic research that has illuminated the genetic underpinnings of PCOS susceptibility. Insights into the intricate interplay of hormonal imbalances within PCOS and dysregulations in sex hormones, insulin, and other signaling molecules that contribute to PCOS symptomatology are discussed. A detailed examination of research into insulin resistance unveils its intricate connections with PCOS development, providing novel insights. The review emphasizes the role of personalized diagnostic and treatment approaches in harmonizing current research findings. It advocates for tailored strategies that consider each patient's distinct presentation in recognition of PCOS heterogeneity. Ultimately, through a comprehensive assessment of contemporary PCOS research, this paper serves as a guiding light for clinicians and researchers and underscores the need for collaborative, evolving research to deliver targeted therapies.

**Key words:** Endocrine disorders, hormonal imbalance, personalized treatment, polycystic ovary syndrome, reproductive disorders

## INTRODUCTION

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders, impacting around 1 in 10 women globally.<sup>[1]</sup> First described in 1935, PCOS is characterized by hyperandrogenism, chronic anovulation, and polycystic ovaries.<sup>[2]</sup> PCOS poses a huge economic burden due to its strong associations with fertility issues, metabolic abnormalities such as insulin resistance and type 2 diabetes, fatty liver disease, cardiovascular risks, and emotional disorders such as depression and anxiety. However, for a long time, PCOS was poorly understood due to its complex, heterogeneous nature. Over the past few decades, advancements in fields such as genetics, molecular endocrinology, and reproductive medicine have accelerated the pace of PCOS research worldwide.<sup>[3,4]</sup> Large-scale epidemiological studies and clinical trials have helped clarify diagnostic criteria and

management strategies.<sup>[5,6]</sup> Significant research investments have improved comprehension of PCOS etiology, pathogenesis, multi-organ involvement, and long-term health consequences.<sup>[7]</sup>

This increased focus on PCOS research is crucial considering its escalating prevalence in developing countries and associated socioeconomic impacts on affected individuals and families. Gaining deeper insights into disease mechanisms presents opportunities for early detection, targeted therapies, and prevention strategies. Ultimately advancing PCOS

### Address for correspondence:

N. Udaya Kumar, Department of Pharmaceutical Chemistry, MB School of Pharmaceutical Sciences, Mohan Babu University, Tirupati, Andhra Pradesh, India. Phone: 9949389761. E-mail: uday307@gmail.com

**Received:** 29-08-2023

**Revised:** 12-11-2023

**Accepted:** 30-11-2023

research aims to improve care outcomes and quality of life for those living with this common, multifaceted condition.

## UNDERSTANDING PCOS ETIOLOGY

### Genetic predisposition: Recent insights

In recent years, substantial strides have been made in elucidating the genetic underpinnings of PCOS, primarily facilitated by large-scale genome-wide association studies. These endeavors have yielded crucial insights by identifying over 60 genomic loci intricately associated with the disorder.<sup>[8]</sup> Within these genomic regions, variants have been pinpointed that exert influence over fundamental pathways implicated in PCOS pathogenesis. Notably, genes governing androgen biosynthesis and signaling, pathways intertwined with obesity, metabolic homeostasis, and circadian rhythms have emerged as pivotal players.<sup>[9]</sup>

Complementary investigations into rare genetic variants have further enriched our understanding. These inquiries have spotlighted occurrences of copy number variations and single nucleotide polymorphisms, implicating genes that orchestrate insulin signaling and the intricate Wnt pathway. These findings not only underscore the multifaceted molecular framework involved in PCOS but also emphasize the intertwined nature of hormonal dysregulation and metabolic perturbations in the syndrome's etiology.<sup>[10]</sup>

Of paramount significance are ongoing longitudinal studies that capitalize on multi-omics approaches. These studies, leveraging advancements in genomics, epigenomics, transcriptomics, and more, hold the promise of unearthing novel genetic and epigenetic biomarkers. These molecular signatures, once deciphered, could offer diagnostic precision, enabling early identification of PCOS and facilitating the stratification of therapeutic strategies based on individual genetic profiles.<sup>[11]</sup> The emerging biomarkers for PCOS subtyping are listed in Table 1.<sup>[10-12]</sup> The amalgamation of these multifaceted investigations augments our comprehension of PCOS at both the genetic and functional levels, laying a formidable foundation

for an era of personalized therapeutic interventions and a deeper appreciation of the syndrome's complexity.<sup>[12]</sup>

### Hormonal imbalances and their implications

The intricate landscape of PCOS is notably characterized by perturbations in hormonal dynamics, particularly the elevation of androgen levels. These disturbances reverberate through intricate mechanisms, exerting a multifaceted influence on vital reproductive processes, including folliculogenesis, ovulation, and endometrial function.<sup>[13]</sup>

The origin of androgen excess is rooted in a dysregulated hypothalamic–pituitary–ovarian axis. This perturbation sets off a cascade of events characterized by heightened secretion of gonadotropin-releasing hormone (GnRH), resulting in excessive luteinizing hormone (LH) secretion, and the subsequent hyperplasia of ovarian theca cells. The cumulative effect of these cascades is the amplification of androgen synthesis and release, thereby leading to a characteristic hyperandrogenic state observed in PCOS.<sup>[14]</sup>

Further compounding these dynamics is the intricate interplay with insulin. Hyperinsulinemia, commonly observed in PCOS, exerts a notable influence on androgen production. It achieves this through the activation of hormone-sensitive lipase present in adipose tissue. This molecular interplay synergistically augments androgen biosynthesis, adding an additional layer of complexity to the hormonal milieu of PCOS.<sup>[15]</sup>

The consequences of these hormonal derangements extend beyond the realm of reproduction. They manifest in a broader physiological context, notably impacting cardiovascular, metabolic, and mental well-being. The intricate link between PCOS and increased cardiovascular risk, metabolic syndrome components, and psychological disturbances underscores the far-reaching consequences of these hormonal imbalances.<sup>[16]</sup>

### Unraveling the role of insulin resistance

Deciphering the intricate role of insulin resistance in the context of PCOS has shed light on a pivotal aspect of the syndrome's

**Table 1: Emerging biomarkers for PCOS subtyping and predictive outcomes**

Biomarker	Role	Potential Applications
Genomic variants	Genetic predisposition	Individualized risk assessment, hereditary factors
Metabolites	Metabolic perturbations	Predicting type 2 diabetes risk, metabolic profiling
Inflammatory markers	Inflammation indicators	Stratifying cardiovascular risks, identifying inflammation
AMH levels	Ovarian reserve and function	Refining PCOS subtypes, assessing reproductive potential
Gut microbiota	Gut health and systemic effects	Linking metabolic health, personalizing dietary advice
Circulating microRNAs	Molecular regulators	Uncovering dysregulated pathways, potential therapeutic targets
AMH	Ovarian function	Tailoring fertility interventions, assessing response to treatment
Telomere length	Cellular aging and health	Predicting long-term disease risks, understanding aging impact

AMH: Anti-Müllerian hormone, PCOS: Polycystic ovary syndrome

pathophysiology. Clinical observations and histological investigations collectively underscore the prominence of adipose tissue insulin resistance, representing a central hallmark.<sup>[17]</sup>

The intricate interplay between genetics and PCOS susceptibility has come into focus through compelling data. Polymorphisms in critical genes, such as IRS-1, adiponectin, leptin, and GLUT4, which intricately govern energy homeostasis and glycemic control pathways, have been implicated in predisposition to PCOS.<sup>[18]</sup> These genetic associations underscore the intricate genetic architecture underlying insulin resistance in PCOS and its potential contribution to metabolic dysregulation.

Importantly, chronic low-grade inflammation has emerged as a key contributor to the impairment of insulin signaling transduction. This inflammatory milieu significantly interferes with the normal cascade of events downstream of insulin receptor activation, further exacerbating insulin resistance. These inflammatory signals, emanating from both adipose tissue and beyond, weave a complex tapestry that underlies the deranged metabolic milieu observed in PCOS.<sup>[19]</sup>

Animal models have offered valuable mechanistic insights into the multifaceted nature of insulin resistance in PCOS. These models highlight the disrupted functioning of the endoplasmic reticulum, a vital cellular organelle involved in protein folding and lipid metabolism, as well as mitochondrial dysfunction, as potential etiological factors. These mechanistic revelations add a layer of depth to our understanding, offering potential therapeutic avenues for intervention.<sup>[20]</sup>

## EMERGING PATHOPHYSIOLOGICAL PARADIGMS

### Inflammation and its impact on PCOS

The burgeoning comprehension of PCOS pathophysiology introduces a paradigm shift with the spotlight on inflammation as a pivotal player. Both clinical observations and biochemical markers converge to implicate chronic low-grade inflammation as an intrinsic component of PCOS development and its associated complications.<sup>[21]</sup>

Central to this connection is the compelling association between adiposity and the orchestrated secretion of proinflammatory cytokines. Adipose tissue expansion, particularly within the visceral depot, serves as a potent source of proinflammatory mediators such as tumor necrosis factor- $\alpha$  and interleukin-6. These cytokines, orchestrators of the inflammatory cascade, act as key players in the disruptive landscape of PCOS.<sup>[22]</sup>

Mechanistically, these cytokines intricately disrupt insulin signaling through pathways like c-Jun N-terminal kinase and

I $\kappa$ B kinase, thereby fostering insulin resistance — a hallmark of PCOS. Furthermore, their influence extends to hepatic processes, promoting the production of apolipoprotein A1 and perpetuating a dysregulated metabolic milieu.<sup>[23]</sup>

A notable facet of this paradigm is the infiltration of macrophages, immune cells known for their inflammation-propagating role, into key ovarian compartments. The ovarian stroma and theca cells are not exempt from this inflammatory influx, thereby aggravating the local inflammatory microenvironment. This orchestrated cascade contributes to the observed hyperandrogenism and menstrual irregularities characteristic of PCOS.<sup>[24]</sup>

Addressing this inflammatory nexus presents a novel therapeutic avenue. Anti-inflammatory medications have garnered attention for their potential in mitigating insulin resistance, ameliorating hyperandrogenism, and even restoring ovulation. This approach holds the promise of concurrently targeting multiple facets of PCOS pathology, signifying a breakthrough in management strategies.<sup>[25]</sup> The multifaceted interactions in the pathophysiology of PCOS are illustrated in Figure 1.


### Gut microbiota-brain axis: Linking the gut and reproductive health

A novel avenue in comprehending PCOS pathophysiology arises from the intricate interplay between the gut microbiome and the brain, spotlighting the gut microbiota-brain axis as a pivotal mediator. This intricate connection underscores the profound influence of the gut microbiome on a spectrum of host functions, including metabolism, immune response, and the intricate network of neurotransmitter and neuroendocrine pathways.<sup>[17,26]</sup>

Significantly, the dysregulation of the gut microbiota composition and its metabolic functions has garnered attention in the context of PCOS. Research unveils distinctive shifts in microbial populations, with decreased *Lactobacillus* and *Bifidobacterium* and heightened *Enterobacteriaceae* and *Streptococcus* prevalence noted among PCOS subjects. These microbiota alterations are not solely confined to the gut but extend their influence to various systemic perturbations linked with PCOS.<sup>[27]</sup>

Remarkably, interventions targeting the gut microbiome, such as prebiotic and probiotic therapies, have showcased their capacity to exert favorable effects. These therapies demonstrate the potential to enhance insulin sensitivity, alleviate inflammation, and ameliorate clinical symptoms through intricate gut-brain signaling mechanisms.<sup>[28]</sup>

This gut-brain interface is reinforced by intricate communication pathways, notably the vagus nerve, orchestrating cross-talk between the gut and the brain.



**Figure 1:** The multifaceted landscape of polycystic ovary syndrome pathophysiology

Furthermore, this nexus extends its influence to the regulation of the hypothalamic-pituitary axis, governing the secretion of GnRH critical to reproductive health. Through this conduit, the gut microbiome can exert a modulatory influence on reproductive function, delineating the profound interconnectedness of these systems.<sup>[29]</sup>

### Clinical manifestations and diagnostic innovations

PCOS's clinical landscape extends beyond its reproductive manifestations, encompassing a spectrum of long-term metabolic and psychological implications. The syndrome's intricate interplay with metabolic dysregulation is emblematic of its far-reaching consequences. Notably, the association between PCOS and an elevated risk of pre-diabetes, type 2 diabetes, and non-alcoholic fatty liver disease underscores the perturbed metabolic milieu it fosters. This intricate relationship with metabolic dysfunction further magnifies the risk of cardiovascular disease and even obstructive sleep apnea, often originating from central adiposity and the hallmark of insulin resistance.<sup>[30]</sup>

In parallel, the psychological facets intertwined with PCOS's clinical canvas are pivotal to comprehend. The burden of PCOS extends beyond the physiological realm, encroaching upon mental well-being. The syndrome's ripple effects are felt in the realm of psychological comorbidities, including depression and anxiety. Furthermore, the psychosocial impact resonates with a reduced quality of life, with implications rooted in hirsutism, the stigma of obesity, and the intricate complexities of fertility struggles.<sup>[13,14]</sup>

Embracing a holistic perspective, early screening, and timely interventions prove pivotal. Addressing the latent metabolic deteriorations through prompt identification and lifestyle counseling holds significance, particularly as these

disturbances often manifest silently. The recognition of PCOS's extended footprint — encompassing both metabolic and psychological dimensions — underscores the necessity of comprehensive care. Moreover, understanding the intricate entanglement of these aspects underscores the importance of an interdisciplinary approach, where medical and psychological interventions converge, ultimately enhancing the overall quality of life for individuals affected by PCOS.<sup>[31]</sup>

### Advancements in diagnostic criteria and imaging techniques

The landscape of PCOS diagnosis has undergone significant evolution, marked by strides in diagnostic criteria and imaging methodologies. The seminal Rotterdam 2003 criteria served as a pivotal milestone, ushering in a more comprehensive understanding by integrating ultrasound findings. This augmentation extended the phenotype spectrum, ensuring a more inclusive approach to PCOS diagnosis.<sup>[32]</sup>

In parallel, the assessment of androgen levels and hyperandrogenism has witnessed redefinition, refining the diagnostic toolkit. Novel avenues have emerged, such as modified anti-Müllerian hormone levels and ovarian volume cutoffs derived from advanced 3D ultrasound techniques. These novel parameters offer heightened precision in characterizing ovarian morphology and function, enhancing the diagnostic accuracy and clinical relevance of PCOS evaluation.<sup>[33]</sup>

Embracing cutting-edge technologies, magnetic resonance-based techniques have contributed to refining vascularity assessments. This has pivotal implications for stratifying cardiometabolic risks associated with PCOS, enhancing our ability to comprehensively assess cardiovascular health in affected individuals.<sup>[34]</sup>

On the horizon of diagnostic innovation, novel blood markers have garnered attention, spanning lipid profiles, adipokine levels, and inflammatory markers. These biochemical signatures provide a deeper insight into the intricate metabolic and inflammatory disturbances characteristic of PCOS.<sup>[35]</sup>

Furthermore, the convergence of clinical, lifestyle, omics, and symptom data is a noteworthy endeavor. The culmination of these diverse datasets facilitates the pursuit of precision medicine. By leveraging this multidimensional information, the goal of personalized and targeted management strategies for PCOS comes into focus. This shift toward precision medicine acknowledges the heterogeneity of PCOS presentations, fostering tailored interventions that hold promise for enhanced therapeutic efficacy and improved patient outcomes.

## BREAKTHROUGHS IN PCOS MANAGEMENT

### Personalized treatment strategies

Recognizing the multifaceted nature of PCOS and its varied presentations, treatment strategies have undergone a paradigm shift toward personalization. The cornerstone of this approach lies in tailoring interventions to the unique characteristics of each individual, considering the wide spectrum of manifestations that PCOS entails.<sup>[36]</sup>

Central to these personalized treatment goals is the restoration of hormonal equilibrium. Aiming to normalize LH levels, reduce excessive androgens, and address insulin resistance, the treatment framework seeks to rectify core pathophysiological drivers. An additional focus is placed on reestablishing ovulation and fertility, addressing one of the central concerns for those affected by PCOS.<sup>[15]</sup>

At the core of this approach are risk-stratified algorithms, designed to harmonize various facets in the decision-making process. These algorithms seamlessly integrate the individual's phenotype, existing comorbidities, and patient-centered priorities, culminating in tailored therapeutic choices. The first-line interventions encompass a spectrum of options, ranging from lifestyle modifications to pharmacological agents.<sup>[13,14]</sup>

Lifestyle modifications stand as a foundational pillar, recognized for their potential to positively impact PCOS manifestations. These modifications, including dietary adjustments and exercise regimens, are tailored to the individual's metabolic profile and health needs. Alongside lifestyle changes, oral contraceptives, metformin, and anti-androgen agents emerge as frontline pharmacological interventions. Each option is selected based on the individual's clinical profile and therapeutic goals.<sup>[14]</sup>

### Lifestyle interventions: Diet, exercise, and stress management

Embracing lifestyle interventions as a cornerstone of PCOS management heralds a holistic approach that encompasses diet, exercise, and stress management. This multifaceted strategy acknowledges the powerful role these factors play in mitigating the intricate pathophysiology of PCOS.<sup>[15]</sup>

Weight management assumes a pivotal role and even modest weight loss yields substantial therapeutic impact. This is achieved through the harmonization of calorie restriction and regular physical activity, which collectively ameliorate insulin sensitivity while concurrently curtailing inflammation — a hallmark of PCOS-associated metabolic disturbances.

Dietary interventions form a crucial facet of this approach, with the Mediterranean diet emerging as a particularly promising contender. Its emphasis on whole foods, healthy fats, lean proteins, and abundant fruits and vegetables aligns well with the metabolic needs of individuals with PCOS. This dietary paradigm not only addresses metabolic irregularities but also offers a sustainable and enjoyable nutritional regimen.<sup>[16]</sup>

The nexus between stress and PCOS is another dimension that lifestyle interventions effectively address. Incorporating practices such as yoga and mindfulness into daily routines can notably alleviate psychological stress. These practices facilitate a holistic approach by fostering emotional well-being, which often intersects with the psychosocial aspects of PCOS.<sup>[15]</sup> What sets lifestyle interventions apart is their potential for long-lasting impact. This approach transcends mere symptom management, offering durable solutions that extend beyond the immediate clinical context.

## PHARMACOLOGICAL ADVANCEMENTS AND NOVEL THERAPIES

### Second-line agents: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and thiazolidinediones (TZDs)

Beyond the first-line interventions, a range of second-line agents play a crucial role in the multifaceted management of PCOS. Notably, GLP-1 RAs and TZDs emerge as compelling therapeutic options. GLP-1 RAs, recognized for their role in glycemic control, offer a versatile avenue for individuals with PCOS exhibiting insulin resistance. These agents enhance insulin sensitivity and exert positive effects on body weight, making them an appealing choice in addressing metabolic irregularities. Similarly, TZDs, known for their insulin-sensitizing properties, exhibit efficacy in mitigating insulin resistance. By targeting adipose tissue and skeletal muscle, TZDs contribute to enhanced glucose utilization, thereby augmenting glycemic control — an essential facet in PCOS management.<sup>[29]</sup>

### Anti-androgens: Managing hirsutism

Anti-androgens, exemplified by spironolactone and flutamide, emerge as pivotal players in managing the distressing symptoms of hirsutism. By counteracting the excess androgen activity characteristic of PCOS, these agents curtail the growth of unwanted facial and body hair, enhancing the overall well-being and confidence of individuals.<sup>[28]</sup>

### Advanced therapies on the horizon: Gluconeogenesis inhibitors and sodium-glucose transporter 2 (SGLT2) blockers

The therapeutic landscape for PCOS continues to evolve with advanced interventions on the horizon. Gluconeogenesis inhibitors and SGLT2 blockers stand as promising candidates in this domain. Gluconeogenesis inhibitors target the intricate pathways involved in excessive glucose production, a hallmark of PCOS. By curtailing this process, these agents hold the potential in mitigating hyperinsulinemia — a core contributor to the syndrome's metabolic perturbations. SGLT2 blockers, renowned for their role in diabetes management, also offer promise in PCOS. By acting on renal glucose reabsorption, these agents foster glycosuria, resulting in improved glycemic control and the potential for addressing hyperinsulinemia.<sup>[27]</sup> The advanced therapies and future directions in the management of PCOS are listed in Table 2.<sup>[26,29,36]</sup>

### Exploratory avenues: Bariatric procedures, osteopathic and acupuncture treatments

Exploring the realm of alternative interventions, bariatric procedures, and complementary therapies such as osteopathic manipulative treatments and acupuncture warrants consideration. Bariatric procedures, while primarily utilized for weight management, have demonstrated effects on hormonal balance and metabolic improvements in PCOS.

Complementary therapies such as osteopathic manipulation and acupuncture offer intriguing avenues for symptom alleviation. While their mechanisms warrant further investigation, they contribute to a comprehensive approach that addresses the broader dimensions of PCOS health.<sup>[19]</sup>

### Emerging frontiers: Stem cell therapy and RNA interference-based approaches

At the forefront of innovation, emerging personalized interventions encompass stem cell therapy and RNA interference-based approaches. Stem cell therapy, leveraging the regenerative potential of stem cells, holds promise in restoring hormonal equilibrium and ameliorating the underlying pathophysiological drivers of PCOS. RNA interference-based strategies, on the other hand, tap into the realm of molecular precision. By selectively silencing genes implicated in PCOS pathogenesis, these approaches hold the potential to recalibrate the intricate molecular cascades responsible for the syndrome's manifestations.<sup>[17,26]</sup>

## ENVIRONMENTAL INFLUENCES AND FUTURE CONSIDERATIONS

### Endocrine disruptors and their potential role in PCOS

The intricate interplay between environmental factors and PCOS etiology has garnered increasing attention, with a spotlight on endocrine disruptors. This subset of chemicals, encompassing phthalates, bisphenols, and heavy metals often found in plastics, pesticides, and environmental pollutants, has raised concerns due to their potential to interfere with hormonal pathways. Of particular concern is the heightened vulnerability of fetuses and infants to the impact of endocrine disruptors. During these crucial developmental periods, susceptibility to disruption is amplified, and the consequences

**Table 2: Advanced therapies and future directions in PCOS management**

Therapy	Mechanism of action	Potential applications
Stem cell therapy	Regenerative potential	Restoring hormonal balance, addressing underlying pathophysiology
RNA interference	Gene silencing at the molecular level	Targeted molecular interventions, personalized care
Global registries	Longitudinal disease tracking	Monitoring chronic disease risks, personalized care
Epigenetic modulation	Modifying gene expression patterns	Addressing genetic predisposition, personalized interventions
Microbiome modulation	Balancing gut microbiota composition	Metabolic improvement, potential hormonal regulation
Nanomedicine	Targeted drug delivery using nanoparticles	Precision therapy delivery, reducing side effects
Telemedicine	Remote patient monitoring and support	Enhancing access to specialized care, improving adherence
Artificial intelligence	Data analysis and prediction	Tailoring interventions, personalized treatment plans
3D bioprinting	Tissue engineering for reproductive health	Restoring ovarian function, fertility enhancement

may reverberate over the lifespan. These chemicals can impede the normal functioning of endocrine systems, potentially setting the stage for hormonal imbalances characteristic of PCOS.<sup>[35]</sup> The environmental endocrine disruptors that can cause PCOS are listed in Table 3.<sup>[33-35]</sup>

Research endeavors have unveiled intriguing associations between higher exposure to endocrine disruptors and the emergence of PCOS features later in life. A noteworthy correlation is the link between elevated exposure and an increase in waist circumference — a recognized component of the PCOS phenotype. Furthermore, long-term consequences, such as the manifestation of PCOS-related traits decades after exposure, have been observed, underscoring the latent and lasting impact of these environmental factors. A pivotal avenue of exploration lies in comprehending the role of endocrine disruptors during critical developmental windows. Gaining insight into the specific time frames during which these chemicals exert maximal influence could illuminate preventive strategies.<sup>[23,24]</sup> By addressing exposure during these vulnerable periods, there is potential to curtail the risk of PCOS development and its associated complications.

### Future directions in PCOS research and translational implications

The trajectory of PCOS research is set to evolve with the advent of prospective birth cohort studies. These endeavors hold the potential to unveil the intricate interplay between genetic predisposition and environmental influences across

the lifespan. By tracing gene-environment interactions from prenatal origins through various life stages, these studies promise to offer a comprehensive understanding of the developmental roots of PCOS. This deepened insight into prenatal origins could provide crucial clues for early interventions and preventive strategies.<sup>[21,22]</sup>

### Omics technologies and personalized approaches

The integration of omics technologies, spanning genomics, epigenomics, proteomics, and metabolomics, is poised to revolutionize PCOS research. By unraveling the molecular intricacies underpinning PCOS, these approaches hold the key to identifying novel biomarkers. These biomarkers could refine patient subtyping, predict disease outcomes, and validate therapeutic targets. This personalized approach promises to usher in a new era of precision medicine, where interventions are tailored to the individual's unique genetic and molecular profile.<sup>[12,37]</sup> The integration of omics for personalized treatment of PCOS is illustrated in Figure 2.


### Regenerative approaches and curative potentials

Emerging on the horizon are regenerative approaches that leverage the potential of stem and progenitor cells. These cutting-edge strategies hold the promise of not just managing but potentially curing PCOS. By harnessing the regenerative capabilities of these cells, there is potential to restore hormonal

**Table 3: Environmental endocrine disruptors and potential effects on PCOS**

Endocrine disruptor	Sources	Mechanisms of action	Potential PCOS impact
Phthalates	Plastics, personal care products	Hormone mimicry, endocrine disruption	Hormonal imbalances, insulin resistance, and reproductive health disturbances
Bisphenols	Plastics, canned foods	Estrogenic effects, hormonal disruption	Altered reproductive health, metabolic disturbances, and endocrine system dysregulation
Heavy metals	Air/water pollution, pesticides	Disruption of endocrine signaling	Aggravated PCOS features, metabolic complications, and oxidative stress
Parabens	Cosmetics, personal care products	Estrogenic effects, hormone interference	Hormonal imbalances, potential disruption of ovarian function
PFAS	Non-stick coatings, water-resistant materials	Endocrine disruption, hormone interference	Metabolic disturbances, potential impact on ovarian function
Organophosphate pesticides	Agricultural use	Neuroendocrine disruption, oxidative stress	Hormonal imbalances, the potential impact on neuroendocrine system
PBDEs	Flame retardants, electronics	Disruption of thyroid hormone function	Thyroid-related disturbances, potential influence on hormonal balance
PCBs	Industrial pollutants	Disruption of endocrine signaling, inflammation	Potential effects on hormonal balance, metabolic complications
Dioxins	Industrial byproducts	Hormone mimicry, endocrine disruption	Disruption of hormonal balance, potential metabolic and reproductive effects

PCBs: Polychlorinated biphenyls, PBDEs: Polybrominated diphenyl ethers, PFAS: Perfluoroalkyl substances, PCOS: Polycystic ovary syndrome



**Figure 2:** Integrating omics technologies for polycystic ovary syndrome personalization

balance and ameliorate the core pathophysiological drivers of PCOS, offering transformative curative possibilities.<sup>[10]</sup>

### Global registries and long-term chronic disease risks

The establishment of global registries designed to monitor long-term chronic disease risks marks a significant step toward comprehensive PCOS care. These registries enable the tracking of individuals over extended periods, shedding light on the evolution of PCOS-related complications and chronic diseases. This longitudinal perspective paves the way for targeted and personalized interventions that address the evolving health needs of those affected by PCOS.<sup>[25]</sup>

### Translational research alliances and clinical integration

Effective translation of research findings into clinical practice necessitates robust collaborations across disciplines. Translational research alliances are poised to bridge the gap between multidisciplinary research insights and real-world clinical applications. By expediting the transition of findings from bench to bedside, these alliances ensure that the latest breakthroughs directly benefit individuals navigating the complexities of PCOS.<sup>[20]</sup>

### Advancing holistic understanding through collaborative efforts

The future of PCOS research lies in collaborative endeavors that extend across borders and disciplines. This holistic understanding necessitates a global approach, where researchers, clinicians, and policymakers work hand in hand. As we unravel the intricacies of PCOS, collaborative efforts are poised to enhance diagnostics, refine interventions, and ultimately improve the quality of life for millions of individuals worldwide. In the pursuit of comprehensive PCOS management, these collective endeavors remain not just important but essential.<sup>[29]</sup>

## CONCLUSION

This review provides a concise synthesis of the intricate landscape of PCOS, drawing from contemporary research and advanced techniques. Progress in understanding the disorder's diverse genetic makeup and underlying pathophysiology is notable. The interplay of metabolic, endocrine, and inflammatory factors, alongside psychological aspects, is shaping a more comprehensive perspective of PCOS. Diagnostic and treatment approaches are becoming more personalized, though the challenge of swift multidisciplinary



translation remains. Exploring prenatal and environmental influences could offer prevention insights, while longitudinal studies on chronic disease risks promise enhanced clinical management. Collaborative endeavors merging molecular, clinical, and epidemiological data hold the potential to revolutionize PCOS precision medicine. Through ongoing global research, more effective strategies can be crafted to enhance the quality of life for those affected by this prevalent condition.

## ACKNOWLEDGMENT

The authors would like to thank Chancellor Padma Sri Dr. Manchu. Mohan Babu Garu and Pro-Chancellor Mr. Vishnu Manchu Garu, MB School of Pharmaceutical Sciences, MBU for providing a good environment for the preparation of this review work.

## REFERENCES

- Azziz R. Polycystic ovary syndrome. *Obstet Gynecol* 2018;132:321-36.
- Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, *et al.* Polycystic ovary syndrome. *Nat Rev Dis Primers* 2016;2:16057.
- Ehrmann DA. Polycystic ovary syndrome. *N Engl J Med* 2005;352:1223-36.
- Franks S. Polycystic ovary syndrome. *N Engl J Med* 1995;333:853-61.
- Guzick DS. Polycystic ovary syndrome. *Obstet Gynecol* 2004;103:181-93.
- Homburg R. Polycystic ovary syndrome. *Best Pract Res Clin Obstet Gynaecol* 2008;22:261-74.
- Joham AE, Norman RJ, Stener-Victorin E, Legro RS, Franks S, Moran LJ, *et al.* Polycystic ovary syndrome. *Lancet Diabetes Endocrinol* 2022;10:668-80.
- McCartney CR, Marshall JC. Polycystic ovary syndrome. *N Engl J Med* 2016;375:54-64.
- Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. *Lancet* 2007;370:685-97.
- Badawy A, Elnashar A. Treatment options for polycystic ovary syndrome. *Int J Womens Health* 2011;3:25-35.
- Escobar-Morreale HF. Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. *Nat Rev Endocrinol* 2018;14:270-84.
- Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. *Int J Obes Relat Metab Disord* 2002;26:883-96.
- Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis. *Nat Rev Endocrinol* 2011;7:219-31.
- Shahid R, Iahtisham-Ul-Haq, Mahnoor, Awan KA, Iqbal MJ, Munir H, *et al.* Diet and lifestyle modifications for effective management of polycystic ovarian syndrome (PCOS). *J Food Biochem* 2022;46:e14117.
- Thakur D, Saurabh Singh DS, Tripathi M, Lufang D. Effect of yoga on polycystic ovarian syndrome: A systematic review. *J Bodyw Mov Ther* 2021;27:281-6.
- Xu Y, Qiao J. Association of insulin resistance and elevated androgen levels with polycystic ovarian syndrome (PCOS): A review of literature. *J Healthc Eng* 2022;2022:9240569.
- Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. *Best Pract Res Clin Obstet Gynaecol* 2004;18:671-83.
- Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. *Ann Intern Med* 2000;132:989-93.
- Meier RK. Polycystic ovary syndrome. *Nurs Clin North Am* 2018;53:407-20.
- Nandi A, Chen Z, Patel R, Poretsky L. Polycystic ovary syndrome. *Endocrinol Metab Clin North Am* 2014;43:123-47.
- Sam S, Dunaif A. Polycystic ovary syndrome: Syndrome XX? *Trends Endocrinol Metab* 2003;14:365-70.
- Taylor AE. Polycystic ovary syndrome. *Endocrinol Metab Clin North Am* 1998;27:877-902, ix.
- Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. *Clin Endocrinol (Oxf)* 2004;60:1-17.
- Balen A, Michelmore K. What is polycystic ovary syndrome? Are national views important? *Hum Reprod* 2002;17:2219-27.
- Goudas VT, Dumesic DA. Polycystic ovary syndrome. *Endocrinol Metab Clin North Am* 1997;26:893-912.
- Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. *Clin Epidemiol* 2013;6:1-13.
- Williams T, Mortada R, Porter S. Diagnosis and treatment of polycystic ovary syndrome. *Am Fam Physician* 2016;94:106-13.
- Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. *Metabolism* 2018;86:33-43.
- Bachelot A. Polycystic ovarian syndrome: Clinical and biological diagnosis. *Ann Biol Clin (Paris)* 2016;74:661-7.
- Collée J, Mawet M, Tebache L, Nisolle M, Brichant G. Polycystic ovarian syndrome and infertility: Overview and insights of the putative treatments. *Gynecol Endocrinol* 2021;37:869-74.
- Zehravi M, Maqbool M, Ara I. Depression and anxiety in women with polycystic ovarian Syndrome: A literature survey. *Int J Adolesc Med Health* 2021;33:367-73.
- Mirza FG, Tahlak MA, Rjeili RB, Hazari K, Ennab F, Hodgman C, *et al.* Polycystic ovarian syndrome (PCOS): Does the challenge end at conception? *Int J Environ Res Public Health* 2022;19:14914.
- Jiang VS, Hawkins SD, McMichael A. Female pattern hair loss and polycystic ovarian syndrome: More than just hirsutism. *Curr Opin Endocrinol Diabetes Obes* 2022;29:535-40.

34. Ibáñez L, Oberfield SE, Witchel S, Auchus RJ, Chang RJ, Codner E, *et al.* An international consortium update: Pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. *Horm Res Paediatr* 2017;88:371-95.
35. Dabravolski SA, Nikiforov NG, Eid AH, Nedosugova LV, Starodubova AV, Popkova TV, *et al.* Mitochondrial dysfunction and chronic inflammation in polycystic ovary syndrome. *Int J Mol Sci* 2021;22:3923.
36. Belenkaia LV, Lazareva LM, Walker W, Lizneva DV, Suturina LV. Criteria, phenotypes and prevalence of polycystic ovary syndrome. *Minerva Ginecol* 2019;71:211-23.
37. Norman RJ, Wu R, Stankiewicz MT. Polycystic ovary syndrome. *Med J Aust* 2004;180:132-7.

**Source of Support:** Nil. **Conflicts of Interest:** None declared.